Recent Company News

• 07:36 PM ET Dec 03, 2025
  

  NovaBridge Biosciences to present new Phase 1 data for ragistomig at ESMO-IO ($3.85, 0.00)

• 01:12 PM ET Nov 03, 2025
  

  INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB

• 08:24 AM ET Nov 05, 2025
  

  StreetAccount Summary - US Pre-market trading

• 01:23 AM ET Nov 07, 2025
  

  StreetAccount Summary - Hong Kong equity offerings 1-Nov to 7-Nov

• 09:16 AM ET Nov 05, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 11:16 AM ET Oct 29, 2025
  

  I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform